Cellectis S.A. (NASDAQ:CLLS) to Post Q1 2023 Earnings of ($0.25) Per Share, Oppenheimer Forecasts

Cellectis S.A. (NASDAQ:CLLSGet Rating) – Analysts at Oppenheimer issued their Q1 2023 earnings per share (EPS) estimates for shares of Cellectis in a report issued on Monday, March 13th. Oppenheimer analyst H. Singh anticipates that the biotechnology company will earn ($0.25) per share for the quarter. Oppenheimer currently has a “Outperform” rating and a $13.00 target price on the stock. The consensus estimate for Cellectis’ current full-year earnings is ($1.28) per share. Oppenheimer also issued estimates for Cellectis’ Q2 2023 earnings at ($0.41) EPS, Q3 2023 earnings at ($0.39) EPS, Q4 2023 earnings at ($0.38) EPS, FY2023 earnings at ($1.42) EPS, FY2024 earnings at ($0.92) EPS, FY2025 earnings at ($0.72) EPS and FY2026 earnings at $2.12 EPS.

Several other analysts have also weighed in on the company. Citigroup reduced their price objective on Cellectis from $36.00 to $24.00 in a research note on Wednesday, December 14th. StockNews.com initiated coverage on Cellectis in a research note on Thursday. They issued a “hold” rating on the stock. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $6.00 price objective on shares of Cellectis in a research note on Monday. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $10.33.

Cellectis Stock Performance

CLLS opened at $1.86 on Thursday. The business’s fifty day moving average is $2.66 and its 200-day moving average is $2.53. The firm has a market cap of $103.38 million, a P/E ratio of -0.78 and a beta of 2.13. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.65 and a current ratio of 2.28. Cellectis has a 52-week low of $1.80 and a 52-week high of $5.04.

Hedge Funds Weigh In On Cellectis

Hedge funds have recently made changes to their positions in the stock. Capital Wealth Alliance LLC bought a new position in shares of Cellectis during the second quarter worth about $680,000. Principal Financial Group Inc. increased its holdings in Cellectis by 11.0% in the second quarter. Principal Financial Group Inc. now owns 1,348,312 shares of the biotechnology company’s stock worth $3,816,000 after purchasing an additional 133,587 shares in the last quarter. Vanguard Group Inc. bought a new stake in Cellectis in the third quarter worth approximately $197,000. Susquehanna International Group LLP bought a new stake in Cellectis in the fourth quarter worth approximately $122,000. Finally, Envestnet Asset Management Inc. increased its holdings in Cellectis by 26.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 57,447 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 11,928 shares in the last quarter. 22.61% of the stock is currently owned by institutional investors.

About Cellectis

(Get Rating)

Cellectis SA operates as a clinical stage biotechnological company. The firm operates through the segments: Therapeutics and Plants. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and monogenic diseases. The Plants segment focuses on using Calyxt’s proprietary PlantSpringTM technology platform to engineer plant metabolism to produce innovative, high-value, and sustainable materials and products for use in helping customers meet their sustainability targets and financial goals.

Featured Stories

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.